These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28288041)

  • 1. Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses.
    Coates EE; Costner PJ; Nason MC; Herrin DM; Conant S; Herscovitch P; Sarwar UN; Holman L; Mitchell J; Yamshchikov G; Koup RA; Graham BS; Millo CM; Ledgerwood JE;
    Clin Nucl Med; 2017 May; 42(5):329-334. PubMed ID: 28288041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.
    Herrin DM; Coates EE; Costner PJ; Kemp TJ; Nason MC; Saharia KK; Pan Y; Sarwar UN; Holman L; Yamshchikov G; Koup RA; Pang YY; Seder RA; Schiller JT; Graham BS; Pinto LA; Ledgerwood JE
    Hum Vaccin Immunother; 2014; 10(12):3446-54. PubMed ID: 25483691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females.
    Haskins-Coulter T; Southern J; Andrews N; Miller E
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28319456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and Characteristics of Nodal and Deltoid FDG and
    Schroeder DG; Jang S; Johnson DR; Takahashi H; Navin PJ; Broski SM; Thorpe MP; Johnson GB; Young JR
    AJR Am J Roentgenol; 2021 Nov; 217(5):1206-1216. PubMed ID: 34009000
    [No Abstract]   [Full Text] [Related]  

  • 5. Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by
    Win Z; Weiner Rd J; Listanco A; Patel N; Sharma R; Greenwood A; Maertzdorf J; Mollenkopf HJ; Pizzoferro K; Cole T; Bodinham CL; Kaufmann SHE; Denoel P; Del Giudice G; Lewis DJM
    Front Immunol; 2020; 11():613496. PubMed ID: 33613536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine.
    Burger IA; Husmann L; Hany TF; Schmid DT; Schaefer NG
    Clin Nucl Med; 2011 Oct; 36(10):848-53. PubMed ID: 21892032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
    Zurek Munk-Madsen M; Toft L; Kube T; Richter R; Ostergaard L; Søgaard OS; Tolstrup M; Kaufmann AM
    Hum Vaccin Immunother; 2018 Apr; 14(4):909-916. PubMed ID: 29172992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort.
    Artemchuk H; Eriksson T; Poljak M; Surcel HM; Dillner J; Lehtinen M; Faust H
    J Infect Dis; 2019 Jan; 219(4):582-589. PubMed ID: 30239832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination.
    Shirone N; Shinkai T; Yamane T; Uto F; Yoshimura H; Tamai H; Imai T; Inoue M; Kitano S; Kichikawa K; Hasegawa M
    Ann Nucl Med; 2012 Apr; 26(3):248-52. PubMed ID: 22271546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake.
    Eifer M; Tau N; Alhoubani Y; Kanana N; Domachevsky L; Shams J; Keret N; Gorfine M; Eshet Y
    J Nucl Med; 2022 Jan; 63(1):134-139. PubMed ID: 33893188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination.
    Thomassen A; Lerberg Nielsen A; Gerke O; Johansen A; Petersen H
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):894-8. PubMed ID: 21340453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term regulation of local cytokine production following immunization in mice.
    Nakayama T; Kashiwagi Y; Kawashima H
    Microbiol Immunol; 2018 Feb; 62(2):124-131. PubMed ID: 29266448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gardasil 9--a broader HPV vaccine.
    Med Lett Drugs Ther; 2015 Mar; 57(1465):47-8. PubMed ID: 25853579
    [No Abstract]   [Full Text] [Related]  

  • 16. The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic
    Şan H; Alagöz E
    Mol Imaging Radionucl Ther; 2022 Oct; 31(3):179-190. PubMed ID: 36268854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
    Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ
    Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.